Nicotine reduction: Strategic research plan

Nicotine and Tobacco Research

Volumn 15, Issue 6, 2013, Pages 1003-1013

  Hatsukami, Dorothy K ^a   Benowitz, Neal L ^b   Donny, Eric ^c   Henningfield, Jack ^d   Zeller, Mitch ^d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d PINNEY ASSOCIATES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETALDEHYDE; AMMONIA; MENTHOL; MONOAMINE OXIDASE INHIBITOR; NICOTINE; UREA; BIOLOGICAL MARKER;

HEALTH CARE MANAGEMENT; MARKET; NEUROIMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SIMULATION; SMOKING; TOBACCO; ANCESTRY GROUP; ANIMAL; HUMAN; PREVENTION AND CONTROL; PROCEDURES; RESEARCH; SMOKING CESSATION; STANDARDS; UNITED STATES;

ANIMALS; BIOLOGICAL MARKERS; CONTINENTAL POPULATION GROUPS; HUMANS; NICOTINE; RESEARCH; SMOKING; SMOKING CESSATION; TOBACCO PRODUCTS; UNITED STATES;

EID: 84877836901     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/nts214     Document Type: Review

References (80)

1. Adam, T., McAughey, J., McGrath, C., Mocker, C., & Zimmermann, R. (2009). Simultaneous on-line size and chemical analysis of gas phase and particulate phase of cigarette mainstream smoke. Analytical and Bioanalytical Chemistry, 394(4), 1193-1203. doi:10.1007/s00216-009-2784-y
2. American Medical Association. (1998). 1998 annual meeting of the American Medical Association, reports of the Council on Scientific Affairs. Retrieved from http://www.ama-assn. org/resources/doc/csaph/csaa-98.pdf
3. Anonymous. (1999). The engineering of Canadian cigarettes: Legacy Tobacco Documents Library. Retrieved from http:// legacy.library.ucsf.edu/tid/tae73a99/pdf
4. Azizian, A., Monterosso, J., O'Neill, J., & London, E. D. (2009). Magnetic resonance imaging studies of cigarette smoking. Handbook of Experimental Pharmacology, 192, 113-143. doi:10.1007/978-3-540-69248-5_5
5. Benowitz, N. L., Dains, K. M., Hall, S. M., Stewart, S., Wilson, M., Dempsey, D., & Jacob, P., 3rd. (2012). Smoking behavior and exposure to tobacco toxicants during 6 months of smoking progressively reduced nicotine content cigarettes. Cancer Epidemiology, Biomarkers & Prevention, 21(5), 761-769. doi:10.1158/1055-9965.EPI-11-0644
6. Benowitz, N. L., Hall, S. M., Stewart, S., Wilson, M., Dempsey, D., & Jacob, P., 3rd. (2007). Nicotine and carcinogen exposure with smoking of progressively reduced nicotine content cigarette. Cancer Epidemiology, Biomarkers & Prevention, 16(11), 2479-2485. doi:10.1158/1055-9965.EPI-07-0393
7. Benowitz, N. L., & Henningfield, J. E. (1994). Establishing a nicotine threshold for addiction. The implications for tobacco regulation. New England Journal of Medicine, 331(2), 123-125.
8. Benowitz, N. L., Jacob, P., 3rd, & Herrera, B. (2006). Nicotine intake and dose response when smoking reduced-nicotine content cigarettes. Clinical Pharmacology and Therapeutics, 80(6), 703-714. doi:10.1016/j.clpt.2006.09.007
9. Breland, A. B., Buchhalter, A. R., Evans, S. E., & Eissenberg, T. (2002). Evaluating acute effects of potential reducedexposure products for smokers: Clinical laboratory methodology. Nicotine & Tobacco Research, 4(Suppl. 2), 131-140. doi:10.1080/1462220021000032780
10. Brody, A. L., Mandelkern, M. A., Costello, M. R., Abrams, A. L., Scheibal, D., Farahi, J.,.. Mukhin, A. G. (2009). Brain nicotinic acetylcholine receptor occupancy: Effect of smoking a denicotinized cigarette. International Journal of Neuropsychopharmacology, 12(3), 305-316. doi:10.1017/S146114570800922X
11. Brody, A. L., Mandelkern, M. A., London, E. D., Childress, A. R., Lee, G. S., Bota, R. G.,.. Jarvik, M. E. (2002). Brain metabolic changes during cigarette craving. Archives of General Psychiatry, 59(12), 1162-1172.
12. Brody, A. L., Mandelkern, M. A., London, E. D., Olmstead, R. E., Farahi, J., Scheibal, D.,.. Mukhin, A. G. (2006). Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors. Archives of General Psychiatry, 63(8), 907-915. doi:10.1001/archpsyc.63.8.907
13. Brody, A. L., Mandelkern, M. A., Olmstead, R. E., Allen-Martinez, Z., Scheibal, D., Abrams, A. L.,.. London, E. D. (2009). Ventral striatal dopamine release in response to smoking a regular vs a denicotinized cigarette. Neuropsychopharmacology, 34(2), 282-289. doi:10.1038/npp.2008.87
14. Buchhalter, A. R., Schrinel, L., & Eissenberg, T. (2001). Withdrawal-suppressing effects of a novel smoking system: Comparison with own brand, not own brand, and denicotinized cigarettes. Nicotine & Tobacco Research, 3(2), 111-118. doi:10.1080/14622200110042636
15. Carmella, S. G., Chen, M., Han, S., Briggs, A., Jensen, J., Hatsukami, D. K., & Hecht, S. S. (2009). Effects of smoking cessation on eight urinary tobacco carcinogen and toxicant biomarkers. Chemical Research in Toxicology, 22(4), 734-741. doi:10.1021/tx800479s
16. Carter, L. P., & Griffiths, R. R. (2009). Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug and Alcohol Dependence, 105(Suppl. 1), S14-S25. doi:10.1016/j.drugalcdep.2009.04.003
17. Carter, L. P., Stitzer, M. L., Henningfield, J. E., O'Connor, R. J., Cummings, K. M., & Hatsukami, D. K. (2009). Abuse liability assessment of tobacco products including potential reduced exposure products. Cancer Epidemiology, Biomarkers and Prevention, 18(12), 3241-3262. doi:10.1158/1055-9965.EPI-09-0948
18. Centers for Disease Control and Prevention. (2011). Ten great public health achievements-Worldwide, 2001-2010. MMWR Morbidity & Mortality Weekly Report, 60(24), 814-818.
19. Centers for Disease Control and Prevention. (2012). Global health-Global health initiatives. Atlanta, GA: Author. Retrieved from http://www.cdc.gov/globalhealth/ghi/countries/countries.htm
20. Creighton, D. E. (1988). The significance of pH in tobacco and tobacco smoke: Legacy Tobacco Documents Library. Retrieved from http://legacy.library.ucsf.edu/tid/kjz02i00/ pdf
21. D'Souza, M. S., & Markou, A. (2011). Neuronal mechanisms underlying development of nicotine dependence: Implications for novel smoking-cessation treatments. Addiction Science & Clinical Practice, 6(1), 4-16.
22. Donny, E. C., Houtsmuller, E., & Stitzer, M. L. (2007). Smoking in the absence of nicotine: Behavioral, subjective and physiological effects over 11 days. Addiction, 102(2), 324-334. doi:10.1111/j.1360-0443.2006.01670.x
23. Donny, E. C., & Jones, M. (2009). Prolonged exposure to denicotinized cigarettes with or without transdermal nicotine. Drug and Alcohol Dependence, 104(1-2), 23-33. doi:10.1016/j.drugalcdep.2009.01.021
24. Donny, E. C., Taylor, T. G., LeSage, M. G., Levin, M., Buffalari, D. M., Joel, D.,.. Sved, A. F. (2012). The impact of tobacco regulation on animal research: New perspectives and opportunities. Nicotine & Tobacco Research. Advance online publication. doi:10.1093/ntr/nts162
25. Ernst, M., Matochik, J. A., Heishman, S. J., Van Horn, J. D., Jons, P. H., Henningfield, J. E.,.. London, E. D. (2001). Effect of nicotine on brain activation during performance of a working memory task. Proceedings of the National Academy of Sciences of the United States of America, 98(8), 4728-4733. doi:10.1073/pnas.061369098
26. Fix, B. V., O'Connor, R. J., Fong, G. T., Borland, R., Cummings, K. M., & Hyland, A. (2011). Smokers' reactions to FDA regulation of tobacco products: Findings from the 2009 ITC United States survey. BMC Public Health, 11, 941. doi:10.1186/1471-2458-11-941
27. Food and Drug Administration. (2010). Draft guidance for industry: Assessment of abuse of potential of drugs. Retrieved from http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/UCM198650.pdf
28. Ghahremani, D. G., Galvan, A., Baker, C. M., McGlennen, K. M., Poldrack, R. A., & London, E. D. (2011, June 18-23). Functional connectivity of insula cortex in human adolescent smokers and non-smokers. Oral presentation at the College on Problems of Drug Dependence Annual Meeting, Hollywood, FL.
29. Goodwin, R. D., Pagura, J., Spiwak, R., Lemeshow, A. R., & Sareen, J. (2011). Predictors of persistent nicotine dependence among adults in the United States. Drug and Alcohol Dependence, 118(2-3), 127-133. doi:10.1016/j.drugalcdep.2011.03.010
30. Gordon, D. L. (1992). PM's global strategy: Marlboro product technology. San Francisco: Legacy Tobacco Documents Library, University of California, San Francisco. Retrieved from http://legacy.library.ucsf.edu/tid/uft21f00
31. Gotti, C., Zoli, M., & Clementi, F. (2006). Brain nicotinic acetylcholine receptors: Native subtypes and their relevance. Trends in Pharmacological Sciences, 27(9), 482-491. doi:10.1016/j.tips.2006.07.004
32. Gray, N., Henningfield, J. E., Benowitz, N. L., Connolly, G. N., Dresler, C., Fagerstrom, K.,.. Boyle, P. (2005). Toward a comprehensive long term nicotine policy. Tobacco Control, 14(3), 161-165. doi:10.1136/tc.2004.010272
33. Greenwald, M. K., & Hursh, S. R. (2006). Behavioral economic analysis of opioid consumption in heroin-dependent individuals: Effects of unit price and pre-session drug supply. Drug and Alcohol Dependence, 85(1), 35-48. doi:10.1016/j.drugalcdep.2006.03.007
34. Harris, A. C., Pentel, P. R., Burroughs, D., Staley, M. D., & Lesage, M. G. (2011). A lack of association between severity of nicotine withdrawal and individual differences in compensatory nicotine self-administration in rats. Psychopharmacology (Berl), 217(2), 153-166. doi:10.1007/s00213-011-2273-9
35. Harris, A. C., Stepanov, I., Pentel, P. R., & Lesage, M. G. (2012). Delivery of nicotine in an extract of a smokeless tobacco product reduces its reinforcement-attenuating and discriminative stimulus effects in rats. Psychopharmacology (Berl), 220(3), 565-576. doi:10.1007/s00213-011-2514-y
36. Hatsukami, D., Benowitz, N. L., Rennard, S. I., Oncken, C., & Hecht, S. S. (2006). Biomarkers to assess the utility of potential reduced exposure tobacco products. Nicotine & Tobacco Research, 8(4), 600-622. doi:10.1080/14622200600858166
37. Hatsukami, D., Biener, L., Leischow, S. J., & Zeller, M. R. (2012). Tobacco and nicotine product testing. Nicotine & Tobacco Research, 14(1), 7-17. doi:10.1093/ntr/ntr027
38. Hatsukami, D., Jensen, J., Anderson, A., Broadbent, B., Allen, S., Zhang, Y., & Severson, H. (2011). Oral tobacco products: Preference and effects among smokers. Drug and Alcohol Dependence, 118(2-3), 230-236. doi:10.1016/j.drugalcdep.2011.03.026
39. Hatsukami, D., Kotlyar, M., Hertsgaard, L. A., Zhang, Y., Carmella, S. G., Jensen, J. A.,.. Hecht, S. S. (2010). Reduced nicotine content cigarettes: Effects on toxicant exposure, dependence and cessation. Addiction, 105(2), 343-355. doi:10.1111/j.1360-0443.2009.02780.x
40. Hatsukami, D., Perkins, K. A., Lesage, M. G., Ashley, D. L., Henningfield, J. E., Benowitz, N. L.,.. Zeller, M. (2010). Nicotine reduction revisited: Science and future directions. Tobacco Control, 19(5), e1-e10. doi:10.1136/tc.2009.035584
41. Hecht, S. S., Yuan, J. M., & Hatsukami, D. (2010). Applying tobacco carcinogen and toxicant biomarkers in product regulation and cancer prevention. Chemical Research in Toxicology, 23(6), 1001-1008. doi:10.1021/tx100056m
42. Henningfield, J., Benowitz, N. L., Slade, J., Houston, T. P., Davis, R. M., & Deitchman, S. D. (1998). Reducing the addictiveness of cigarettes. Council on Scientific Affairs, American Medical Association. Tobacco Control, 7(3), 281-293. doi:10.1136/tc.7.3.281
43. Hursh, S. R., Galuska, C. M., Winger, G., & Woods, J. H. (2005). The economics of drug abuse: A quantitative assessment of drug demand. Molecular Interventions, 5(1), 20-28. doi:10.1124/mi.5.1.6
44. Hursh, S. R., & Silberberg, A. (2008). Economic demand and essential value. Psychological Review, 115(1), 186-198. doi:10.1037/0033-295X.115.1.186
45. Institute of Medicine. (2012). Scientific standards for studies on modified risk tobacco products. Washington, DC: National Academies Press.
46. Kassel, J. D., Evatt, D. P., Greenstein, J. E., Wardle, M. C., Yates, M. C., & Veilleux, J. C. (2007). The acute effects of nicotine on positive and negative affect in adolescent smokers. Journal of Abnormal Psychology, 116(3), 543-553. doi:10.1037/0021-843X.116.3.543
47. Kassel, J. D., Greenstein, J. E., Evatt, D. P., Wardle, M. C., Yates, M. C., Veilleux, J. C., & Elssenberg, T. (2007). Smoking topography in response to denicotinized and high-yield nicotine cigarettes in adolescent smokers. Journal of Adolescent Health, 40(1), 54-60. doi:10.1016/j.jadohealth.2006.08.006
48. Kuryatov, A., Berrettini, W., & Lindstrom, J. (2011). Acetylcholine receptor (AChR) alpha5 subunit variant associated with risk for nicotine dependence and lung cancer reduces (alpha4beta2)alpha5 AChR function. Molecular Pharmacology, 79(1), 119-125. doi:10.1124/mol.110.066357
49. Lanza, S. T., Donny, E. C., Collins, L. M., & Balster, R. L. (2004). Analyzing the acquisition of drug self-administration using growth curve models. Drug and Alcohol Dependence, 75(1), 11-21. doi:10.1016/j.drugalcdep.2004.02.006
50. Lasser, K., Boyd, J. W., Woolhandler, S., Himmelstein, D. U., McCormick, D., & Bor, D. H. (2000). Smoking and mental illness. Journal of American Medical Association, 284(20), 2606-2610. doi:10.1001/jama.284.20.2606
51. Neumann, C. L. (1988). Nicotine analogs: Known compounds: Legacy Tobacco Documents Library. Retrieved from http:// legacy.library.ucsf.edu/tid/huv46b00/pdf
52. O'Connor, R. J., Cummings, K. M., Giovino, G. A., McNeill, A., & Kozlowski, L. T. (2006). How did UK cigarette makers reduce tar to 10 mg or less? British Medical Journal, 332(7536), 302. doi:10.1136/bmj.332.7536.302
53. Perkins, K. A., Fonte, C., Sanders, M., Meeker, J., & Wilson, A. (2001). Threshold doses for nicotine discrimination in smokers and non-smokers. Psychopharmacology (Berl), 155(2), 163-170. doi:10.1007/s002130000660
54. Pickworth, W. B., Fant, R. V., Nelson, R. A., Rohrer, M. S., & Henningfield, J. E. (1999). Pharmacodynamic effects of new de-nicotinized cigarttes. Nicotine & Tobacco Research, 1, 357-364. doi:10.1080/14622299050011491
55. Rees, V. W., Kreslake, J. M., Cummings, K. M., O'Connor, R. J., Hatsukami, D. K., Parascandola, M.,.. Connolly, G. N. (2009). Assessing consumer responses to potential reduced-exposure tobacco products: A review of tobacco industry and independent research methods. Cancer Epidemiology, Biomarkers and Prevention, 18(12), 3225-3240. doi:10.1158/1055-9965.EPI-09-0946
56. Rose, J. E., Behm, F. M., Westman, E. C., Mathew, R. J., London, E. D., Hawk, T. C.,.. Coleman, R. E. (2003). PET studies of the influences of nicotine on neural systems in cigarette smokers. American Journal of Psychiatry, 160(2), 323-333. doi:10.1176/appi.ajp.160.2.323
57. Saccone, N. L., Saccone, S. F., Hinrichs, A. L., Stitzel, J. A., Duan, W., Pergadia, M. L.,.. Bierut, L. J. (2009). Multiple distinct risk loci for nicotine dependence identified by dense coverage of the complete family of nicotinic receptor subunit (CHRN) genes. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, 150B(4), 453-466. doi:10.1002/ajmg.b.30828
58. Schlipkoter, U., & Flahault, A. (2010). Communicable diseases: Achievements and challenges for public health. Public Health Reviews, 32(1), 90-119.
59. Shahan, T. A., Bickel, W. K., Badger, G. J., & Giordano, L. A. (2001). Sensitivity of nicotine-containing and de-nicotinized cigarette consumption to alternative non-drug reinforcement: A behavioral economic analysis. Behavioural Pharmacology, 12(4), 277-284.
60. Shahan, T. A., Bickel, W. K., Madden, G. J., & Badger, G. J. (1999). Comparing the reinforcing efficacy of nicotine containing and de-nicotinized cigarettes: A behavioral economic analysis. Psychopharmacology (Berl), 147(2), 210-216. doi:10.1007/s002130051162
61. Smith, J. W., & Stolerman, I. P. (2009). Recognising nicotine: The neurobiological basis of nicotine discrimination. Handbook of Experimental Pharmacology, 192, 295-333. doi:10.1007/978-3-540-69248-5_11
62. Stratton, K., Shetty, P., Wallace, R., & Bondurant, S. (Eds.). (2001). Clearing the smoke: Assessing the science base for tobacco harm reduction. Washington, DC: National Academy Press.
63. Talhout, R., Opperhuizen, A., & van Amsterdam, J. G. (2007). Role of acetaldehyde in tobacco smoke addiction. European Neuropsychopharmacology, 17(10), 627-636. doi:10.1016/j.euroneuro.2007.02.013
64. Tang, D. W., Hello, B., Mroziewicz, M., Fellows, L. K., Tyndale, R. F., & Dagher, A. (2012). Genetic variation in CYP2A6 predicts neural reactivity to smoking cues as measured using fMRI. Neuroimage, 60(4), 2136-2143. doi:10.1016/j.neuroimage.2012.01.119
65. Teague, C., Jr. (1972). R.J. Reynolds confidential research planning memorandum on the nature of the tobacco business and the crucial role of Nicotine therein. Winston-Salem, NC: R.J. Reynolds.
66. Tengs, T. O., Ahmad, S., Savage, J. M., Moore, R., & Gage, E. (2005). The AMA proposal to mandate nicotine reduction in cigarettes: A simulation of the population health impacts. Preventive Medicine, 40(2), 170-180. doi:10.1016/j.ypmed.2004.05.017
67. Thorgeirsson, T. E., Geller, F., Sulem, P., Rafnar, T., Wiste, A., Magnusson, K. P.,.. Stefansson, K. (2008). A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature, 452(7187), 638-642. doi:10.1038/nature06846
68. Tidey, J. W., Rohsenow, D. J., Kaplan, G. B., Swift, R. M., & AhnAllen, C. G. (2012). Separate and combined effects of very low nicotine cigarettes and nicotine replacement in smokers with schoziphrenia and controls. Nicotine & Tobacco Research, 15(1), 121-129. doi:10.1093/ntr/nts098
69. Tuesta, L. M., Fowler, C. D., & Kenny, P. J. (2011). Recent advances in understanding nicotinic receptor signaling mechanisms that regulate drug self-administration behavior. Biochemical Pharmacology, 82(8), 984-995. doi:10.1016/j.bcp.2011.06.026
70. U.S. Department of Health and Human Services. (2010). How tobacco smoke causes disease: The biology and behavioral basis for smoking-attributable disease. A report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health
71. U.S. Department of Health and Human Services. (2012). Preventing tobacco use among youth and young adults: A report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services. Retrieved from http://www.surgeongeneral.gov/library/preventing-youthtobacco-use/index.html
72. Walker, N., Howe, C., Bullen, C., Grigg, M., Glover, M., McRobbie, H.,.. Whittaker, R. (2012). The combined effect of very low nicotine content cigarettes, used as an adjunct to usual Quitline care (nicotine replacement therapy and behavioural support), on smoking cessation: A randomized controlled trial. Addiction. Advance online publication. doi:10.1111/j.1360-0443.2012.03906.x
73. Wang, Z., Faith, M., Patterson, F., Tang, K., Kerrin, K., Wileyto, E. P.,.. Lerman, C. (2007). Neural substrates of abstinenceinduced cigarette cravings in chronic smokers. Journal of Neuroscience, 27(51), 14035-14040. doi:10.1523/JNEUROSCI.2966-07.2007
74. Watson, C. H., Trommel, J. S., & Ashley, D. L. (2004). Solid-phase microextraction-based approach to determine free-base nicotine in trapped mainstream cigarette smoke total particulate matter. Journal of Agricultural and Food Chemistry, 52(24), 7240-7245. doi:10.1021/jf049455o
75. Weinberger, A. H., Desai, R. A., & McKee, S. A. (2010). Nicotine withdrawal in U.S. smokers with current mood, anxiety, alcohol use, and substance use disorders. Drug and Alcohol Dependence, 108(1-2), 7-12. doi:10.1016/j.drugalcdep.2009.11.004
76. World Health Organization. (2012). WHO study group on tobacco product regulation. Report on the scientific basis of tobacco product regulation (Vol. WHO Technical Report Series, no. 967). Geneva, Switzerland: Author. Retrieved from http://www.who.int/tobacco/publications/prod_regulation/ trs_967/en/index.html
77. Yerger, V. B., & McCandless, P. M. (2011). Menthol sensory qualities and smoking topography: A review of tobacco industry documents. Tobacco Control, 20(Suppl. 2), ii37-ii43. doi:10.1136/tc.2010.041988
78. Yuan, J. M., Gao, Y. T., Murphy, S. E., Carmella, S. G., Wang, R., Zhong, Y.,.. Hecht, S. S. (2011). Urinary levels of cigarette smoke constituent metabolites are prospectively associated with lung cancer development in smokers. Cancer Research, 71(21), 6749-6757. doi:10.1158/0008-5472.CAN-11-0209
79. Yuan, J. M., Gao, Y. T., Wang, R., Chen, M., Carmella, S. G., & Hecht, S. S. (2012). Urinary levels of volatile organic carcinogen and toxicant biomarkers in relation to lung cancer development in smokers. Carcinogenesis, 33(4), 804-809. doi:10.1093/carcin/bgs026
80. Zeller, M., Hatsukami, D., & Strategic Dialogue on Tobacco Harm Reduction Group. (2009). The Strategic Dialogue on Tobacco Harm Reduction: A vision and blueprint for action in the US. Tobacco Control, 18(4), 324-332. doi:10.1136/tc.2008.027318